← All trials
NCT03251287
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2017
- Primary completion
- Dec 31, 2018
- Completion date
- Jan 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of East AngliaLead sponsor
- Medical Research CouncilCollaborator
- University of East AngliaOverall official - principal investigator
- University of East AngliaCollaborator
- University of East AngliaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.